Merck’s return to ophthalmology snags first success
Merck’s $1.3 billion upfront bet on EyeBio in 2024 is starting to pay off. The New Jersey drug giant, attempting to expand its therapeutic arsenal beyond Keytruda, reported ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.